Lung Cancer | Specialty

Halmos Zeroes in on Year Ahead for Lung Cancer Treatment

December 15th 2020

Balazs Halmos, MD discusses the year 2021 and how it will encompass a bigger focus on neoadjuvant and adjuvant trials, more novel molecular compounds for more select subgroups, and a migration of circulating tumor DNA into a more minimal residual disease–based setting.

Learning to Tailor Targeted and Immune Therapy in Lung Cancer

December 14th 2020

Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

December 14th 2020

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma

December 14th 2020

Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

Ongoing Research in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Treatment After Progression on Front-Line Therapy in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

First-Line Approach for Treating Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Results from the CASPIAN Trial for Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Results from the IMpower133 Trial for Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Advances in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Rationale for I/O therapy in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Aggressive Nature of Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Differentiating Small Cell Lung Cancer and Non-Small Cell Lung Cancer

December 11th 2020

Background of Small Cell Lung Cancer

December 11th 2020

Dr. Ferrarotto on the Mechanism of Action of Trilaciclib in ES-SCLC

December 10th 2020

Renata Ferrarotto, MD, discusses the mechanism of action of trilaciclib in extensive-stage small cell lung cancer.

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer

December 9th 2020

Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation.

FDA Grants Breakthrough Therapy Designation to Sotorasib for KRAS G12C–Mutant Advanced or Metastatic NSCLC

December 8th 2020

December 8, 2020 - The FDA has granted a breakthrough therapy designation to sotorasib for use as a potential treatment in patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.

Dr. Mok on the Importance of Global Collaboration to Improve Cancer Care

December 3rd 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the importance of improving cancer research through collaboration as a Giant of Cancer Care®.

Lurbinectedin/Doxorubicin Combo Misses OS End Point in Phase 3 SCLC Trial

December 3rd 2020

December 3, 2020 - Lurbinectedin plus doxorubicin failed to significantly improve overall survival versus physician’s choice of topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small cell lung cancer who progressed after 1 previous platinum-containing line of treatment, missing the primary end point of the phase 3 ATLANTIS trial.

FDA Approval Sought for Amivantamab for Metastatic EGFR Exon 20–Positive NSCLC

December 3rd 2020

December 3, 2020 — A biologics license application has been submitted to the FDA for the EGFR-MET bispecific antibody amivantamab for the treatment of patients with metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations who have progressed on or following a platinum-based chemotherapy.